Evidence map›Paper›PMID 29430595›Full record

ArticleThe protein journal2018

The C19S Substitution Enhances the Stability of Hepcidin While Conserving Its Biological Activity.

Edina Pandur, Zsuzsanna Fekete, Kitti Tamási, László Grama, Edit Varga, Katalin Sipos

Abstract read
PubMed Publisher
In one paragraph

Article in The protein journal, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Therapeutic Advances in Regulating the Hepcidin/Ferroportin Axis.Pharmaceuticals (Basel, Switzerland) · 2019
    Review
  2. Hepcidin Therapeutics.Pharmaceuticals (Basel, Switzerland) · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Edina PandurDepartment of Pharmaceutical Biology, Faculty of Pharmacy, University of Pécs, Katalin Sipos, Szigeti str. 12., Pécs, 7624, Hungary.
Zsuzsanna FeketeDepartment of Medical Biology, Medical School, University of Pécs, Pécs, Hungary.
Kitti TamásiDepartment of Pharmaceutical Biology, Faculty of Pharmacy, University of Pécs, Katalin Sipos, Szigeti str. 12., Pécs, 7624, Hungary.
László GramaDepartment of Biophysics, Medical School, University of Pécs, Pécs, Hungary.
Edit VargaDepartment of Pharmaceutical Biology, Faculty of Pharmacy, University of Pécs, Katalin Sipos, Szigeti str. 12., Pécs, 7624, Hungary.
Katalin SiposDepartment of Pharmaceutical Biology, Faculty of Pharmacy, University of Pécs, Katalin Sipos, Szigeti str. 12., Pécs, 7624, Hungary. katalin.sipos@aok.pte.hu.ORCID 0000-0002-6706-2682
University of Pecs · HU

Funding

European Union, European Social Fund EFOP-3.6.1-16-2016-00004University of Pécs, Medical School Research foundation, PTE KA 2015/30019/KAUniversity of Pécs, Pharmaceutic Talent Center program PST 480132
6 · The paper itself

Abstract

Hepcidin, the key hormone of iron homeostasis is responsible for lowering the serum iron level through its interaction with iron exporter ferroportin. Thus, hepcidin agonists provide a promising opportunity in the treatment of iron disorders caused by lacking or decreased hepcidin expression. We investigated the importance of each of the eight highly conserved cysteines for the biological activity of hepcidin. Eight cysteine mutants were created with site directed mutagenesis. The binding ability of these hepcidin mutants to the hepcidin receptor ferroportin was determined using bacterial two-hybrid system and WRL68 human hepatic cells. The biological activity of hepcidin mutants was determined by western blot analysis of ferroportin internalization and ferroportin ubiquitination. To investigate the effect of mutant hepcidins on the iron metabolism of the WRL68 cells, total intracellular iron content was measured with a colorimetric assay. The stability of M6 hepcidin mutant was determined using ELISA technique. Our data revealed that serine substitution of the sixth cysteine (M6) yielded a biologically active but significantly more stable peptide than the original hormone. This result may provide a promising hepcidin agonist worth testing in animal models.

Indexed as

CysteineHepcidinsAmino Acid SubstitutionCell LineHumansModels, MolecularProtein StabilityCysteineHepcidinsCysteineHepcidinHepcidin agonist

Identifiers

PMID29430595
OpenAlexW2790433287

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.